Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
AstraZeneca PLC
AZN
$175.41
Name : AstraZeneca PLC
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $272,046,473,216.00
EPSttm : 7.07
finviz dynamic chart for AZN
AstraZeneca PLC
$175.41
1.87%
$3.35
AZN — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.2

Margin Of Safety %

5

Put/Call OI Ratio

0.48

EPS Next Q Diff

EPS Last/This Y

3.52

EPS This/Next Y

1.2

Price

175.41

Target Price

228.71

Analyst Recom

1.5

Performance Q

5.69

Upside

-11.3%

Beta

0.3

Ticker: AZN




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-21AZN168.460.350.73116946
2026-10-22AZN172.580.360.63116416
2026-10-23AZN171.490.350.60116620
2026-10-26AZN172.090.363.04117078
2026-10-27AZN170.010.391.04120867
2026-10-28AZN169.560.401.40122707
2026-10-29AZN174.50.400.82123135
2026-10-30AZN186.730.410.45125037
2026-11-02AZN186.610.420.55126431
2026-11-03AZN184.130.421.56127568
2026-11-04AZN189.380.430.63128092
2026-11-05AZN186.810.431.36128410
2026-11-06AZN186.420.461.48133388
2026-11-09AZN189.370.462.28133509
2026-11-10AZN186.560.470.67133954
2026-11-11AZN185.540.470.52134498
2026-11-12AZN184.350.470.74134715
2026-11-13AZN184.450.471.30134915
2026-11-16AZN184.090.470.53135111
2026-11-17AZN182.240.470.60135616
2026-11-18AZN178.770.471.36135983
2026-11-19AZN175.40.482.87136856
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-21AZN168.83- 6887.110.05
2026-10-22AZN172.60- 6797.710.05
2026-10-23AZN171.47- 6212.710.05
2026-10-26AZN172.10- 6400.710.05
2026-10-27AZN170.04- 6118.210.05
2026-10-28AZN169.62- 6287.810.05
2026-10-29AZN174.49- 6883.410.05
2026-10-30AZN186.70- 7693.610.05
2026-11-02AZN186.72- 5591.510.05
2026-11-03AZN183.90- 5304.910.16
2026-11-04AZN189.00- 6107.010.12
2026-11-05AZN186.84- 5503.610.12
2026-11-06AZN186.43- 5685.810.12
2026-11-09AZN189.36- 6024.410.12
2026-11-10AZN186.68- 5452.810.12
2026-11-11AZN185.49- 5599.410.12
2026-11-12AZN184.37- 5614.410.12
2026-11-13AZN184.49- 5739.310.12
2026-11-16AZN184.02- 5679.410.12
2026-11-17AZN182.29- 5550.010.12
2026-11-18AZN178.74- 5365.310.12
2026-11-19AZN175.41- 5377.810.12
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-21AZN-0.02-1.050.17
2026-10-22AZN-0.02-1.050.17
2026-10-23AZN-0.02-1.050.17
2026-10-26AZN-0.02-1.000.17
2026-10-27AZN-0.02-1.000.22
2026-10-28AZN-0.02-1.000.22
2026-10-29AZN-0.02-1.000.22
2026-10-30AZN-0.02-1.000.22
2026-11-02AZN-0.02-0.890.22
2026-11-03AZN-0.02-0.890.22
2026-11-05AZN-0.02-0.890.22
2026-11-06AZN-0.02-0.890.22
2026-11-09AZN-0.02-1.120.22
2026-11-10AZN-0.02-1.120.22
2026-11-11AZN-0.02-1.120.20
2026-11-12AZN-0.02-1.120.20
2026-11-13AZN-0.02-1.120.20
2026-11-16AZN-0.020.750.20
2026-11-17AZN-0.020.750.20
2026-11-18AZN-0.020.750.20
2026-11-19AZN-0.020.750.20
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

2.79

Avg. EPS Est. Current Quarter

1.74

Avg. EPS Est. Next Quarter

Insider Transactions

-0.02

Institutional Transactions

0.75

Beta

0.3

Average Sales Estimate Current Quarter

16597

Average Sales Estimate Next Quarter

15977

Fair Value

184.45

Quality Score

94

Growth Score

94

Sentiment Score

33

Actual DrawDown %

17.5

Max Drawdown 5-Year %

-28.7

Target Price

228.71

P/E

24.82

Forward P/E

15.42

PEG

1.38

P/S

4.36

P/B

5.26

P/Free Cash Flow

26.45

EPS

7.07

Average EPS Est. Cur. Y​

10.12

EPS Next Y. (Est.)

11.32

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

17.68

Relative Volume

0.86

Return on Equity vs Sector %

-5.2

Return on Equity vs Industry %

-13.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.05

EBIT Estimation

5377.8
◆ AZN Healthcare
$175.42
📉
Swing / Pullback
Buy the dip on strong trends
52 /100
WEAK
Trend
8/20
Pullback
11/25
Volume
7/15
Valuation
18/20
TP/AR
2/10
Options
6/10
RSI
45.8
Range 1M
32.1%
🚀
Momentum Growth
Ride accelerating trends
N/A
36 /100
WEAK
Momentum
3/25
Growth
17/30
Estimates
6/20
Inst/Vol
4/15
Options
6/10
EPS Yr
12.1%
EPS NY
10.8%
52W%
36.4%
💎
Long-Term Value
Quality companies, undervalued
50 /100
WEAK
🟡 HOLD +28.6% upside
Quality
21/30
Valuation
9/30
Growth
13/25
Stability
4/10
LT Trend
3/5
Upside
+28.6%
Quality
94
MoS
5%
AZN — P/E HistoricalDrug Manufacturers - General
AstraZeneca PLC
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 96100
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
AZN

Latest News

—
Caricamento notizie per AZN…
stock quote shares AZN – AstraZeneca PLC Stock Price stock today
news today AZN – AstraZeneca PLC stock forecast ,stock prediction 2023 2024 2025
marketwatch AZN – AstraZeneca PLC yahoo finance google finance
stock history AZN – AstraZeneca PLC invest stock market
stock prices AZN premarket after hours
ticker AZN fair value insiders trading